Zymeworks Inc. Common Stock
$ 23.63
2.78%
24 Feb - close price
- Market Cap 1,799,433,000 USD
- Current Price $ 23.63
- High / Low $ 23.68 / 22.80
- Stock P/E N/A
- Book Value 4.26
- EPS -0.85
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.18 %
- 52 Week High 28.49
- 52 Week Low 9.03
About
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$36.46
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-04 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-03-06 | 2023-11-07 | 2023-08-10 | 2023-05-08 | 2023-03-07 |
| Reported EPS | -0.26 | 0.03 | -0.3 | -0.31 | -0.39 | -0.49 | -0.42 | -0.2 | -0.41 | -0.76 | -0.36 | 4.65 |
| Estimated EPS | -0.46 | -0.46 | -0.73 | -0.0922 | -0.41 | -0.31 | -0.29 | -0.43 | -0.47 | -0.47 | -0.54 | 4.84 |
| Surprise | 0.2 | 0.49 | 0.43 | -0.2178 | 0.02 | -0.18 | -0.13 | 0.23 | 0.06 | -0.29 | 0.18 | -0.19 |
| Surprise Percentage | 43.4783% | 106.5217% | 58.9041% | -236.2256% | 4.878% | -58.0645% | -44.8276% | 53.4884% | 12.766% | -61.7021% | 33.3333% | -3.9256% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.35 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZYME
2025-12-11 23:09:45
Zymeworks Inc. has achieved a significant breakthrough with its lead cancer drug, Zanidatamab, proving effective in Phase 3 trials, potentially generating billions in sales. This success is poised to invigorate Vancouver's biotech sector by creating jobs, attracting investment, and fostering a skilled workforce. The company also has other promising drugs in its pipeline and plans to diversify by investing in future royalty streams from other biotech firms.
2025-12-10 20:08:58
Zymeworks Inc. has achieved a significant breakthrough with its lead cancer drug, Zanidatamab, which has proven effective in Phase 3 trials and is poised for commercialization, potentially generating billions in sales. This success, along with other promising drugs in its pipeline and strategic investments in other biotech companies, positions Zymeworks as a key player in revitalizing Vancouver's life sciences sector. The company's growth and job creation are expected to create a ripple effect, attracting further investment and talent to the local biotech ecosystem.
2025-11-18 12:57:57
Jazz Pharmaceuticals and Zymeworks' HER2 bispecific antibody Ziihera significantly improved progression-free survival in a Phase III study for gastroesophageal adenocarcinoma, paving the way for a regulatory filing in early 2026. Analysts are optimistic about Ziihera's potential to replace existing HER2-targeting therapies and are projecting peak revenues of around $2.9 billion. The drug works by binding to two sites on the HER2 protein, leading to fewer HER2 receptors on cancer cells and activating the immune system.
2025-11-17 21:09:28
Zymeworks Inc. stock reached a four-year high following promising results from a late-stage human efficacy trial for its lead drug, Ziihera, in combination with chemotherapy for advanced metastatic gastroesophageal adenocarcinoma (GEA). The drug demonstrated statistically significant and clinically meaningful improvements in prolonging the period without cancer worsening or spreading. This development marks a significant turning point for Zymeworks, especially after a period of investor doubt and a strategic shift under its new CEO, Kenneth Galbraith.
2025-11-17 20:08:58
Zymeworks Inc. announced positive topline Phase 3 results for Ziihera (zanidatamab-hrii) in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in progression-free and overall survival. Development partner Jazz Pharmaceuticals plans to file an sBLA in 1H 2026, positioning Ziihera as a potential new first-line standard of care. This breakthrough sent ZYME stock soaring in pre-market trading and could materially alter Zymeworks' financial forecasts and long-term narrative, despite the company remaining loss-making.
2025-10-24 02:02:03
The FDA has granted accelerated approval for Ziihera, a new drug for biliary tract cancer developed by Zymeworks Inc. in partnership with Jazz Pharmaceuticals. This approval triggers a $25-million milestone payment to Zymeworks and makes them eligible for over $1 billion in total milestone payments and royalties. The drug validates Zymeworks' Azymetric bispecific platform technology and marks their first FDA-approved therapy.
